BIP-UPY

Bioactive Implantable Polymers based on UreidoPyrimidinone

 Coordinatore FUNDACIO PRIVADA ASCAMM 

 Organization address address: "AVENIDA UNIVERSITAT AUTONOMA , PARC TECNOLOGIC DEL VALLES 23"
city: CERDANYOLA DEL VALLES
postcode: 8290

contact info
Titolo: Dr.
Nome: Esther
Cognome: Hurtos
Email: send email
Telefono: 34935944700

 Nazionalità Coordinatore Spain [ES]
 Totale costo 5˙918˙893 €
 EC contributo 4˙500˙852 €
 Programma FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies
 Code Call FP7-NMP-2012-LARGE-6
 Funding Scheme CP-IP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-02-01   -   2017-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FUNDACIO PRIVADA ASCAMM

 Organization address address: "AVENIDA UNIVERSITAT AUTONOMA , PARC TECNOLOGIC DEL VALLES 23"
city: CERDANYOLA DEL VALLES
postcode: 8290

contact info
Titolo: Dr.
Nome: Esther
Cognome: Hurtos
Email: send email
Telefono: 34935944700

ES (CERDANYOLA DEL VALLES) coordinator 533˙606.20
2    LIFETEC GROUP BV

 Organization address address: DEN DOLECH GEM 3 116 2
city: EINDHOVEN
postcode: 5612 AZ

contact info
Titolo: Dr.
Nome: Jurgen
Cognome: De Hart
Email: send email
Telefono: +31 40 2474837

NL (EINDHOVEN) participant 631˙400.00
3    SUPRAPOLIX BV

 Organization address address: HORSTEN 1
city: EINDHOVEN
postcode: 5612 AX

contact info
Titolo: Dr.
Nome: Anton
Cognome: Bosman
Email: send email
Telefono: 31402472690

NL (EINDHOVEN) participant 592˙920.00
4    TECHNISCHE UNIVERSITEIT EINDHOVEN

 Organization address address: DEN DOLECH 2
city: EINDHOVEN
postcode: 5612 AZ

contact info
Titolo: Mr.
Nome: Leon
Cognome: Luwijs
Email: send email
Telefono: 31402474313

NL (EINDHOVEN) participant 555˙675.00
5    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Myriam
Cognome: Witvrouw
Email: send email
Telefono: 3216320623
Fax: 3216326515

BE (LEUVEN) participant 551˙000.00
6    NEOS SURGERY SL

 Organization address address: PASEO MIKELETEGI - PARQUE TECNOLOGICO MIRAMON 2
city: DONOSTIA SAN SEBASTIAN
postcode: 20009

contact info
Titolo: Dr.
Nome: Montse
Cognome: Charles-Harris
Email: send email
Telefono: +34 93 5944726
Fax: +34 93 5944737

ES (DONOSTIA SAN SEBASTIAN) participant 433˙920.00
7    POLITECHNIKA LODZKA

 Organization address address: ULICA ZEROMSKIEGO 116
city: LODZ
postcode: 90 924

contact info
Titolo: Dr.
Nome: Radoslaw
Cognome: Wach
Email: send email
Telefono: 48426313164
Fax: 48426840043

PL (LODZ) participant 396˙486.00
8    Chempilots a/s

 Organization address address: Rugmarken 24-26
city: FARUM
postcode: 3520

contact info
Titolo: Mr.
Nome: Christian
Cognome: Elbek
Email: send email
Telefono: 4544951661
Fax: 4544957887

DK (FARUM) participant 341˙796.80
9    Coloplast A/S

 Organization address address: Holtedam 1
city: Humlebaek
postcode: 3050

contact info
Titolo: Ms.
Nome: Pia
Cognome: Nielsen
Email: send email
Telefono: 4549112385

DK (Humlebaek) participant 289˙500.00
10    UNIVERSITAIR ZIEKENHUIS ANTWERPEN

 Organization address address: WILRIJKSTRAAT 10
city: EDEGEM
postcode: 2650

contact info
Titolo: Ms.
Nome: Daisy
Cognome: Van Mieghem
Email: send email
Telefono: 3238213191

BE (EDEGEM) participant 174˙548.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

molecules    health    vitro    bioactive    hospitals    peptide    team    materials    bioactivity    bip    biomedical    embolic    library    situ    initial    polymers    mechanical    care    material    protocols    tissue    risk    implants    assessing    polymeric    supramolecular    complications    first    performing    biocompatibility    rtd    upy    implant    implantable    polymer    tests    methodology    treatments    performance    bioactivities    prototypes    aneurysm    millions    manufacturing    co    medical    ureidopyrimidinone    sterilisation    floor    pelvic   

 Obiettivo del progetto (Objective)

'BIP-UPy addresses the need for biomedical implants which can be easily fine-tuned in their properties in regards to bioactivity, biodegradability, and mechanical performance, and thereby be optimized for their targeted clinical application. This project will develop a library comprising of a selection of synthetic polymers and specific bioactivities which can be used to provide the required properties for a targeted biomedical implant. The polymeric materials that will be addressed are supramolecular UPy-modified polymers for uses in urologic implants and embolic implants, benefitting large population groups: bio-degradable meshes with improved in-situ tissue regeneration in pelvic floor repair and endovascular embolic implants with a reduced aneurysm recurrence risk. A mix-and-match approach will be used to bioactivate these supramolecular base materials. The supramolecular nature of the materials allows for mild processing conditions. Main objective is to develop a methodology for obtaining implantable polymers with specifically designed bioactivity for in-situ Tissue Engineering, in which the medical implant is obtained in one step by co-processing of the peptide molecules with the neat polymeric material. Key deliverables are protocols for processable biocompatible UPy-based polymers synthesis and manufacturing scale-up; protocols for UPy-based polymers bioactivity tailoring; procedures for processing the UPy-based polymers preserving the bioactivity efficiency; sterilisation protocols for bioactive medical implants; bioactive implants prototypes with tailored bioactivities; material and implant biocompatibility and bioactivity tests data; new predictive in-vitro tests and drafts of regulatory docs. BIP-UPy consortium comprises 9 partners from 5 European countries: 3 RTD performing institutions and 2 Hospitals, 3 SMEs and 1 LE representing the strong industrial involvement. Forth SME (CHEMPILOTS-DK) has whithdrawn from project on 31/12/2014.'

Introduzione (Teaser)

Polymer-based implants have improved the quality of life for millions and reduced associated national health care costs. Research institutions together with companies and health institutions are now developing a pelvic floor implant and one to treat brain aneurysms to extend the current implant portfolio.

Descrizione progetto (Article)

Polymers have become ubiquitous, and not only in food packaging and plastics for electronics. Biomedical implants are one of the most important markets for polymers. The total European market for polymers in medical devices is predicted to reach EUR 664.2 million by 2015, an indication of the huge impact on the economy and on public health.

Recognising the critical importance of polymeric medical devices, the EU is co-funding the four-year 'Bioactive implantable polymers based on ureidopyrimidinone' (http://www.bipupy.eu/ (BIP-UPY)) project. The powerful consortium consists of three RTD performing institutions, two hospitals, three small and medium-sized enterprises, and one large enterprise. Targeted applications are pelvic floor dysfunction affecting millions of women worldwide and intracranial aneurysm. Current treatments for these conditions have high rates of associated complications, risks and/or costs.

BIP-UPY consortium is developing a methodology to produce implants with tailored bioactivity from co-processing of the ureidopyrimidinone (UPy) polymers and the peptide molecules. Bioactivity needs to be carefully preserved not only during processing of the materials and implant manufacturing but also during sterilisation of the implant. Both the materials and the prototype implants are assessed for biocompatibility and bioactivity.

Within the first reporting period, the team synthesised different UPy-polymer combinations for each target application. With a focus on commercialisation, all protocols and equipment necessary for large-scale manufacturing have been established. A library of UPy-peptides will assist in assessing bioactivity.

Conceptual designs have been established along with mechanical testing procedures and the first steps towards design verification have been taken. The activities in this regard have supported the delivery of initial prototypes of pelvic floor implant and aneurysm implant.

In addition, the team has begun assessing biocompatibility of the new UPy-polymers both in vitro and in vivo in order to have an initial assessment of the real biomechanical behaviour of the first implants manufactured.

BIP-UPY is paving the way to novel biodegradable implants with tailored bioactivities and excellent mechanical performance to address important medical conditions. Currently available treatments are associated with complications and high risk, so the new technologies will provide welcome relief to patients while reducing the burden on health care systems.

Altri progetti dello stesso programma (FP7-NMP)

RAPIDOS (2013)

Rapid Prototyping of Custom-Made Bone-Forming Tissue Engineering Constructs

Read More  

IMS&CPS (2010)

Innovative Material Synergies & Composite Processing Strategies

Read More  

OPTICIAN2020 (2013)

Flexible and on-demand manufacturing of customised spectacles by close-to-optician production clusters

Read More